title: GEIS guidelines for gastrointestinal sarcomas (GIST).
abstract: Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes(1). On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum. GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists…) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours. Following its introduction, median survival of patients with advanced or metastatic GIST increased from 18 to more than 60months. Sunitinib and Regorafenib are two targeted agents with worldwide approval for second- and third-line treatment, respectively, in metastatic GIST.
authors.affiliation: Instituto Valenciano de Oncología, Calle del Profesor Beltrán Bàguena, 8, 46009 Valencia, Spain. Electronic address: apoveda@fivo.org.
authors.forename: Andrés
authors.initials: A
authors.lastname: Poveda
authors.affiliation: Institut Català d'Oncologia, Avinguda de la Granvia de l'Hospitalet, 199-203, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: García Del Muro
authors.affiliation: Fundación Instituto Valenciano de Oncología, C/ Prof Baguena, 19, 46009 Valencia, Spain.
authors.forename: Jose Antonio
authors.initials: JA
authors.lastname: López-Guerrero
authors.affiliation: Hospital Puerta de Hierro, Calle Manuel de Falla, 1, 28222 Majadahonda, Madrid, Spain.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Cubedo
authors.affiliation: Hospital La Paz, Paseo de la Castellana, 261, 28046 Madrid, Spain.
authors.forename: Virginia
authors.initials: V
authors.lastname: Martínez
authors.affiliation: Instituto Valenciano de Oncología, Calle del Profesor Beltrán Bàguena, 8, 46009 Valencia, Spain.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Romero
authors.affiliation: Hospital Vall d'Hebrón, Passeig de la Vall d'Hebrón, 119-129, 08035 Barcelona, Spain.
authors.forename: César
authors.initials: C
authors.lastname: Serrano
authors.affiliation: Hospital Vall d'Hebrón, Passeig de la Vall d'Hebrón, 119-129, 08035 Barcelona, Spain.
authors.forename: Claudia
authors.initials: C
authors.lastname: Valverde
authors.affiliation: Hospital Virgen del Rocío, Av Manuel Siurot s/n, 41013 Sevilla, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Martín-Broto
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005770:Gastrointestinal Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis / Q000556:secondary / Q000601:surgery / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D010671:Phenylurea Compounds / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; C559147:regorafenib; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D000077210:Sunitinib
keywords: CD117; DOG1; GEIS; GIST; Imatinib; KIT; PDGFRA; Regorafenib; Sunitinib